We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.

Confirm

The world needs better pain treatments


Pain is widely considered the biggest problem in medicine today: a 2011 market research report indicates that more than 1.5 billion people worldwide suffer from chronic pain,1 more than 21% of who suffer for more than 20 years.2 Adequate treatment is often unavailable or hard to access, and as a specialist business focused on this market niche, we’re determined to tackle this problem.

1 Global Industry Analysts, Inc. (2011) Global Pain Management Market to Reach US$60 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. [Online] Available from: http://www.prweb.com/pdfdownload/8052240.pdf [Accessed 14 April 2018].
2 Langley P.C.: The prevalence, correlates and treatment of pain in the European Union. CMRO. 2011;463-480

“Imagine going through your daily life where everything that you touch, or that touches you, where most every noise around you from a passing car to children playing, causes you pain. We will leave no stone unturned to help these patients.”

Gabriel Baertschi

Chief Executive Officer

Our purpose is to change lives for the better. We believe that change is possible. We invest heavily in innovation, exploring new possibilities to develop smart solutions. Success comes from pioneering treatments that transform patients’ lives for the better. This measure of success drives everything we do.

 

Our ambition

By 2022, we will be a €2bn entrepreneurial, science-based company, specializing in pain, gout and beyond and deliver five new medicines to patients with diseases with high unmet needs. We are turbo-charging our delivery from our own research and collaborating with external partners.

 

Our strategy: leading with innovation

We focus our R&D activities on pain and have built up our portfolio with projects “Beyond Pain” and medical devices. This diversifies our risks and opens new markets for us.

 

“As a worldwide leader in pain management, we are looking for strategic partnerships in research and development to bring innovative solutions to patients with indications with high unmet medical needs. Innovation is at our core and as a fully integrated pharmaceutical company, we can offer support along the whole value chain – from drug development to commercialization.”

Gabriel Baertschi

Chief Executive Officer

Get to know us

 

Grünenthal by the numbers

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the USA.

Leadership

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach alongside a commitment to diversity and inclusivity.

Current projects

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.


Join us

Imaginative researcher? Unconventional strategist? Forward-thinking go-getter? We would love to hear from you.


Open Innovation: collaboration at the core

We can’t do everything alone, and we have found some excellent partners to share the load. We believe that open collaborations bring together all the expertise that is relevant to develop innovative medicines for patients.

External growth

We are on a strong and solid economic growth path. In the last years, we’ve already made great progress in acquiring external assets and companies. We will continue on this path as it allows us to broaden our portfolio and entrepreneurial basis.

Social Responsibility

Caring for the world around us is a big part of who we are – from a patient’s pain to climate change – we’re committed to doing what we can to tackle these issues, big and small

Global Capabilities

Although firmly rooted in Germany, today we’re very much a growing global business: since spreading our wings beyond Germany in the 1960’s, we have continued to grow steadily.

Pipeline

In our quest to improve the lives of even more patients in need we enrich our expertise in pain management with a complementary diversification into devices and technologies

4/23/2018

Aachen, Germany, 23 April 2018 – Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s research and development organization on 1 July 2018. Currently, Philip holds the role of Global Head of Diabetes Research and Translational Medicine and Chief Scientific Officer at Sanofi’s German Hub in Frankfurt.

4/9/2018

Aachen, Germany and Leuven, Belgium, April 09, 2018 – Grünenthal, the Katholieke Universiteit Leuven’s Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the treatment of painful diseases with a high unmet medical need.

2/1/2018

Aachen, Germany, February 01, 2018 – Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP) designation by the U.S. Food and Drug Administration (FDA) for VIVO. VIVO is a surgical sealant proposed for being an adjunct to standard closure techniques in gastrointestinal procedures to reduce intestinal leakage. VIVO is a candidate from Grünenthal’s innovative development-pipeline of surgical sealants. Flix®, the first product from this portfolio, already obtained CE-Certification in Europe.

1/23/2018

Aachen, Germany, January 19, 2018 – Grünenthal announced today that Adhesys Medical GmbH, a wholly-owned subsidiary of the Grünenthal Group, has received CE-Certification for MAR-CUTIS (Flix®). Flix® is a topical skin adhesive for surgical use and the first product from Grünenthal’s innovative pipeline of surgical sealants. Further products, especially for use inside the body, are under development (MAR-VIVO product family).

1/23/2018

Aachen, January 23, 2018 – Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for distributing, promoting and selling MSD’s Women’s Health products in Brazil, Central America, Colombia, Mexico and Peru. The portfolio comprises several Women’s Health products, including Zoely®, Nuvaring®, Cerazette® and Livial®. MSD will continue to commercialize Nexplanon®/Implanon NXT® throughout that region.

1/15/2018

Aachen and Beijing, January 15, 2018 – Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market and distribute Grünenthal’s Tramal® (tramadol) in China from May 1, 2018.